Stock BIO.B BIO-RAD LABORATORIES, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Bio-Rad Laboratories, Inc. Nyse

Equities

BIO.B

US0905721082

Market Closed - Nyse
Other stock markets
 04:15:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
279.9 USD 0.00% Intraday chart for Bio-Rad Laboratories, Inc. 0.00% -12.71%
Apr. 26 Bio-Rad Laboratories, Inc. Announces Executive Vice President and President Changes, Life Science Group CI
Apr. 15 Zacks Investment Research Lowers Price Target on Bio-Rad Laboratories to $285 From $322 MT

Summary

  • The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
  • Overall, and from a short-term perspective, the company presents an interesting fundamental situation.

Strengths

  • The company returns high margins, thereby supporting business profitability.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • The company appears to be poorly valued given its net asset value.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • Over the past twelve months, analysts' opinions have been strongly revised upwards.
  • Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
  • The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
  • Historically, the company has been releasing figures that are above expectations.

Weaknesses

  • According to forecast, a sluggish sales growth is expected for the next fiscal years.
  • The valuation of the company is particularly high given the cash flows generated by its activity.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The overall consensus opinion of analysts has deteriorated sharply over the past four months.

Ratings chart - Surperformance

Sector: Medical Equipment, Supplies & Distribution

1st Jan change Capi. Investor Rating ESG Refinitiv
BIO-RAD LABORATORIES, INC. Stock Bio-Rad Laboratories, Inc.
-12.71% 7.89B -
ABBOTT LABORATORIES Stock Abbott Laboratories
-2.31% 187B
C+
MEDTRONIC PLC Stock Medtronic plc
-3.20% 106B
C
BECTON, DICKINSON AND COMPANY Stock Becton, Dickinson and Company
-5.04% 66.9B
A
DEXCOM, INC. Stock DexCom, Inc.
+0.20% 49.45B
B-
CENCORA, INC. Stock Cencora, Inc.
+17.29% 48B
B-
HOYA CORPORATION Stock Hoya Corporation
+4.06% 40.84B
B+
METTLER-TOLEDO INTERNATIONAL, INC. Stock Mettler-Toledo International, Inc.
+2.07% 26.48B
B
WEST PHARMACEUTICAL SERVICES, INC. Stock West Pharmaceutical Services, Inc.
+2.36% 26.25B
A-
TERUMO CORPORATION Stock Terumo Corporation
+12.96% 24.62B
A-
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. BIO Stock
  4. BIO.B Stock
  5. Ratings Bio-Rad Laboratories, Inc.